LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC

Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer. However, during the course of treatment, cancer cells often develop resistance to gefitinib without fully understood mechanisms. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xinyin, Lu, Xiyi, Zhen, Fuxi, Jin, Shidai, Yu, Tongfu, Zhu, Quan, Wang, Wei, Xu, Kun, Yao, Jiaqi, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424064/
https://www.ncbi.nlm.nih.gov/pubmed/30889481
http://dx.doi.org/10.1016/j.omtn.2019.02.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424064/
https://www.ncbi.nlm.nih.gov/pubmed/30889481
http://dx.doi.org/10.1016/j.omtn.2019.02.010

Ejemplares similares